Impairment of the in vitro Release of Carbamazepine from Tablets

Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formu...

Full description

Bibliographic Details
Main Authors: Alija Uzunović, Edina Vranić, Šeherzada Hadžidedić
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2010-08-01
Series:Bosnian Journal of Basic Medical Sciences
Subjects:
Online Access:http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693
id doaj-1bcbea8fc13e4f4592e51e4ba47f4025
record_format Article
spelling doaj-1bcbea8fc13e4f4592e51e4ba47f40252020-11-25T01:02:25ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBosnian Journal of Basic Medical Sciences1512-86011840-48122010-08-0110310.17305/bjbms.2010.2693417Impairment of the in vitro Release of Carbamazepine from TabletsAlija Uzunović0Edina Vranić1Šeherzada Hadžidedić2Agency for Medical Products and Medical Devices of Bosnia and HerzegovinaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of SarajevoAgency for Medical Products and Medical Devices of Bosnia and HerzegovinaCarbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named “A” and “B” formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market. The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation “B’.’ From the dissolution point of view, this formulation was inferior to the formulation “A, due to the solubilization effect. http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693carbamazepineimpairmentin vitro release
collection DOAJ
language English
format Article
sources DOAJ
author Alija Uzunović
Edina Vranić
Šeherzada Hadžidedić
spellingShingle Alija Uzunović
Edina Vranić
Šeherzada Hadžidedić
Impairment of the in vitro Release of Carbamazepine from Tablets
Bosnian Journal of Basic Medical Sciences
carbamazepine
impairment
in vitro release
author_facet Alija Uzunović
Edina Vranić
Šeherzada Hadžidedić
author_sort Alija Uzunović
title Impairment of the in vitro Release of Carbamazepine from Tablets
title_short Impairment of the in vitro Release of Carbamazepine from Tablets
title_full Impairment of the in vitro Release of Carbamazepine from Tablets
title_fullStr Impairment of the in vitro Release of Carbamazepine from Tablets
title_full_unstemmed Impairment of the in vitro Release of Carbamazepine from Tablets
title_sort impairment of the in vitro release of carbamazepine from tablets
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
series Bosnian Journal of Basic Medical Sciences
issn 1512-8601
1840-4812
publishDate 2010-08-01
description Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named “A” and “B” formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market. The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation “B’.’ From the dissolution point of view, this formulation was inferior to the formulation “A, due to the solubilization effect.
topic carbamazepine
impairment
in vitro release
url http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693
work_keys_str_mv AT alijauzunovic impairmentoftheinvitroreleaseofcarbamazepinefromtablets
AT edinavranic impairmentoftheinvitroreleaseofcarbamazepinefromtablets
AT seherzadahadzidedic impairmentoftheinvitroreleaseofcarbamazepinefromtablets
_version_ 1725205089733312512